Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Coming off a brutal 41-10 loss to Texas A&M, Missouri head coach Eli Drinkwitz was eager to see the way his team would respond. Here's all he had to say after the team's win to round out its non ...

Yet, Eli Lilly's GLP-1 medications are helping it compete with the leader. Plus, Lilly also has several other promising catalysts to consider. These are two of healthcare's biggest darlings right ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the ...

Eli Iserbyt's 2024-25 cyclocross got off to an inauspicious start last week after the Belgian was disqualified from his first race of the season, the Exact Cross in Beringen, for intentionally ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show.

Nico Chen has given his Buy rating due to a combination of factors including Eli Lilly’s strong revenue growth and the potential expansion of its diabetes medication Mounjaro. Chen recognizes ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space. The company's path-breaking innovation in using glucagon-like peptide ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at ...

Also Read: Eli Lilly’s Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron’s Dupixent In the LUCENT-3 trial, mirikizumab helped patients ...